Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NUS1 pseudogene 3 (NUS1P3), also known as YDD19, is classified as a pseudogene unrelated to the protein-coding NUS1 gene. Unlike NUS1—which encodes the Nogo-B receptor (NgBR), a critical subunit in cis-prenyltransferase complexes essential for protein glycosylation, dolichol biosynthesis, and has a clear role in human disease—NUS1P3 has no known coding potential or biological activity[4][5][6]. There are no reports linking NUS1P3 to human disease, drug interaction, or biomarker applications. No molecular function or action has been attributed to NUS1P3 in curated scientific databases. Key clarification: - NUS1 pseudogene 3 (NUS1P3) is distinct from the protein-coding NUS1 gene and should not be mistaken for a functional protein, therapeutic target, or disease gene. NUS1, not NUS1P3, encodes the Nogo-B receptor involved in congenital disorders of glycosylation, neurological diseases, and targets of medical interest[1][3][5][7]. NUS1P3 itself is inactive and is included in gene catalogs due to genetic sequence similarity with NUS1, but it does not code for protein or confer biological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NUS1 pseudogene 3 (NUS1P3).